Recent advances in multimodal treatment for gastric cancer: A review

被引：64

作者：

Lordick F. ^{[1
]}

Siewert J.R. ^{[1
]}

机构：

[1] Klinikum Rechts der Isar, Technical University of Munich, D-81675 Munich

来源：

Gastric Cancer | 2005年 / 8卷 / 2期

关键词：

Adjuvant; Chemotherapy; Gastric cancer; Multimodal; Neoadjuvant; Radiotherapy;

D O I：

10.1007/s10120-005-0321-z

中图分类号：

学科分类号：

摘要：

The prognosis after surgical treatment of gastric cancer remains poor. This review aims to clarify the indication for multimodal treatment of gastric cancer. A systematic literature research and evaluation of clinical data presented at important international cancer meetings were undertaken. Recently published results of large randomized phase III trials underscore the potential value of neoadjuvant chemotherapy or adjuvant chemoradiotherapy in gastric cancer. However, data from randomized controlled trials are still scarce, and it remains uncertain which subgroups of patients should routinely undergo multimodal treatment. In view of the side effects of pre- and foremost postoperative therapies, a more distinct definition of prognostic and predictive markers is warranted. Neoadjuvant chemotherapy is a rising option in locally advanced gastric cancer. Adjuvant chemoradiation has been shown to be beneficial in gastric cancer patients who have undergone suboptimal surgical resection. The benefits of adjuvant chemotherapy alone seem to be very small. © 2005 by International and Japanese Gastric Cancer Associations.

引用

页码：78 / 85

页数：7

共 60 条

[1] Hundahl S.A., Menck H.R., Mansour E.G., Winchester D.P., The National Cancer Data Base report on gastric carcinoma, Cancer, 80, pp. 2333-2341, (1997)
[2] Allum W., Cunningham D., Weeden S., Perioperative chemotherapy in operable gastric and lower oesophageal cancer. A randomised controlled trial (the MAGIC trial ISRCTN 93793971), Proc Am Soc Clin Oncol, 998 A, (2003)
[3] Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S., Estes N.C., Stemmermann G.N., Et al., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med, 345, pp. 725-730, (2001)
[4] Bonenkamp J.J., Hermans J., Sasako M., Van De Velde C.J.H., Extended lymph-node dissection for gastric cancer, N Engl J Med, 340, pp. 908-914, (1999)
[5] Hartgrink H.H., Van De Velde C.J.H., Putter H., Bonenkamp J.J., Klein Kranenbarg E., Songun I., Et al., Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the Randomized Dutch Gastric Cancer Group Trial, J Clin Oncol, 22, pp. 2069-2077, (2004)
[6] Mcculloch P., Eidi Nita M., Kazi H., Tsuno H., Nagawa H., Gama-Rodrigues J.J., Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach, Cochrane Data-base Syst Rev, 4, (2003)
[7] Siewert J.R., Bottcher K., Stein H.J., Roder J.R., Relevant prognostic factors in gastric cancer, Ann Surg, 228, pp. 449-461, (1998)
[8] Maruyama K., Sasako M., Kinoshita T., Sano T., Katai H., Hada M., Et al., Current controversies in cancer: Should systematic lymph node dissection be recommended for gastric cancer?, Eur J Cancer, 34, pp. 1480-1489, (1998)
[9] Van De Velde C.J.H., Peeters K.C.M.J., The gastric cancer controversy, J Clin Oncol, 21, pp. 2234-2236, (2003)
[10] Siewert J.R., Feith M., Werner M., Stein H.J., Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/topographic classification in 1002 consecutive patients, Ann Surg, 232, pp. 353-361, (2000)

← 1 2 3 4 5 6 →